β-Adrenergic receptor polymorphisms: Relationship to the β-agonist controversy and clinical implications

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 18, 2007, Pages 3195-3203

  Taylor, D Robin ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

2 adrenoceptor; agonist; albuterol; asthma; salbutamol; salmeterol

Indexed keywords

ARGININE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; SALBUTAMOL; SALMETEROL;

ASTHMA; DRUG POTENTIATION; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; HUMAN; REVIEW;

ADRENERGIC BETA-AGONISTS; ALBUTEROL; ARGININE; ASTHMA; GENOTYPE; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-2;

EID: 40949153161     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.8.18.3195     Document Type: Review

References (50)

1. O'BYRNE PM, ADELROTH E: β2 déjà vu. Chest (2006) 129:3-5.
2. SEARS MR, TAYLOR DR, PRINT CG et al.: Regular inhaled β-agonist treatment in bronchial asthma. Lancet (1990) 336:1391-1396.
3. CRANE J, PEARCE N, FLATT A et al.: Prescribed fenoterol and death from asthma in New Zealand, 1981-83: case-control study. Lancet (1989) 1:917-922.
4. CRANE J, PEARCE N, BURGESS C, JACKSON R, BEASLEY R: End of New Zealand asthma epidemic. Lancet (1995) 345:984-985.
5. NELSON HS, WEISS ST, BLEECKER ER, YANCEY SW, DORINSKY PM: The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest (2006) 129:15-26.
6. US FOOD AND DRUGS ADMINISTRATION: Medwatch safety information and adverse event reporting program: 2003 safety alert-serevent, salmeterol xinafoate. Cold Spring Harbor, HY (2003).
7. US FOOD AND DRUGS ADMINISTRATION: Labeling changes for drug products that contain salmeterol. FDA Newspage (2003).
8. SEARS MR, TAYLOR DR: The β 2-agonist controversy. Observations, explanations and relationship to asthma epidemiology. Drug Saf. (1994) 11:259-283.
9. MCGRAW DW, ALMOOSA KF, PAUL RJ, KOBILKA BK, LIGGETT SB: Antithetic regulation by β-adrenergic receptors of Gq receptor signaling via phospholipase C underlies the airway β-agonist paradox. J. Clin. Invest. (2003) 112:619-626.
10. SHORE SA, DRAZEN JM: β-agonists and asthma: too much of a good thing? J. Clin. Invest. (2003) 112:495-497.
11. HANEY S, HANCOX RJ: Rapid onset of tolerance to β-agonist bronchodilation. Respir. Med. (2005) 99:566-571.
12. SHORE SA, LAPORTE J, HALL I P, HARDY E, PANETTIERI RA Jr: Effect of IL-1 β on responses of cultured human airway smooth muscle cells to bronchodilator agonists. Am. J. Respir. Cell Mol. Biol. (1997) 16:702-712.
13. ALDRIDGE RE, HANCOX RJ, TAYLOR DR et al.: Effects of terbutaline and budesonide on sputum cells and bronchial hyperresponsiveness in asthma. Am. J. Respir. Crit. Care Med. (2000) 161:1459-1464.
14. WRAIGHT JM, SMITH AD, COWAN JO et al.: Adverse effects of short-acting p-agonists: potential impact when anti-inflammatory therapy is inadequate. Respirology (2004) 9:215-221.
15. TAYLOR DR, SEARS MR: Regular p-adrenergic agonists. Evidence, not reassurance, is what is needed. Chest (1994) 106:552-559.
16. REIHSAUS E, INNIS M, MACINTYRE N, LIGGETT SB: Mutations in the gene encoding for the p2-adrenergic receptor in normal and asthmatic subjects. Am. J. Respir. Cell Mol. Biol. (1993) 8:334-339.
17. GREEN SA, COLE G, JACINTO M, INNIS M, LIGGETT SB: A polymorphism of the human p 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J. Biol. Chem. (1993) 268:23116-21.
18. GREEN SA, TURKI J, BEJARANO P, HALL IP, LIGGETT SB: Influence of p 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am. J. Respir. Cell Mol. Biol. (1995) 13:25-33.
19. GREEN SA, TURKI J, INNIS M, LIGGETT SB: Amino-terminal polymorphisms of the human p 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry (1994) 33:9414-9419.
20. DRYSDALE CM, MCGRAW DW, STACK CB et al.: Complex promoter and coding region p 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc. Natl Acad. Sci. USA (2000) 97:10483-8.
21. HAWKINS GA, TANTISIRA K, MEYERS DA et al.: Sequence, haplotype, and association analysis of ADRp2 in a multiethnic asthma case-control study. Am. J. Respir. Crit. Care Med. (2006) 174:1101-1109.
22. SMALL KM, MCGRAW DW, LIGGETT SB: Pharmacology and physiology of human adrenergic receptor polymorphisms. Ann. Rev Pharmacol. Toxicol. (2003) 43:381-411.
23. THAKKINSTIAN A, MCEVOY M, MINELLI C et al.: Systematic review and meta-analysis of the association between {p}2-adrenoceptor polymorphisms and asthma: a HuGE review. Am. J. Epidemiol. (2005) 162:201-211.
24. CONTOPOULOS-IOANNIDIS DG, MANOLI EN, IOANNIDIS JP: Meta-analysis of the association of p2-adrenergic receptor polymorphisms with asthma phenotypes. J. Allergy Clin. Immunol. (2005) 115:963-972.
25. TURKI J, PAK J, GREEN SA, MARTIN RJ, LIGGETT SB: Genetic polymorphisms of the p 2-adrenergic receptor in nocturnal and nonnocturnal asthma. Evidence that Gly16 correlates with the nocturnal phenotype. J. Clin. Invest. (1995) 95:1635-1641.
26. HALL IP, BLAKEY JD, AL BALUSHI KA et al.: p2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet (2006) 368:771-779.
27. ISRAEL E, DRAZEN JM, LIGGETT SB et al.: The effect of polymorphisms of the p(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am. J. Respir. Crit. Care Med. (2000) 162:75-80.
28. ISRAEL E, CHINCHILLI VM, FORD JG et al.: Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet (2004) 364:1505-1512.
29. WECHSLER ME, LEHMAN E, LAZARUS SC et al.: p-adrenergic receptor polymorphisms and response to salmeterol. Am. J. Respir. Crit. Care Med. (2006) 173:519-526.
30. TAYLOR DR, DRAZEN JM, HERBISON GP et al.: Asthma exacerbations during long term p agonist use: influence of p(2) adrenoceptor polymorphism. Thorax (2000) 55:762-767.
31. HANCOX RJ, SEARS MR, TAYLOR DR: Polymorphism of the p2-adrenoceptor and the response to long-term p2-agonist therapy in asthma. Eur. Respir. J. (1998) 11:589-593.
32. TATTERSFIELD AE, HARRISON TW: p-Adrenoceptor polymorphisms: focus moves to long-acting p-agonists. Am. J. Respir. Crit. Care Med. (2006) 173:473-474.
33. LAZARUS SC, BOUSHEY HA, FAHY JV et al.: Long-acting p2-agonist monotherapy versus continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA (2001) 285:2583-2593.
34. LEMANSKE RF, JR., SORKNESS CA, MAUGER EA et al.: Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA (2001) 285:2594-603.
35. PALMER CN, LIPWORTH BJ, LEE S et al.: Arginine-16 p2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax (2006) 61:940-944.
36. LEE DK, CURRIE GP, HALL IP, LIMA JJ, LIPWORTH BJ: The arginine-16 p2-adrenoceptor polymorphism predisposes to bronchoprotective subsensitivity in patients treated with formoterol and salmeterol. Br. J. Clin. Pharmacol. (2004) 57:68-75.
37. BLEECKER ER, YANCEY SW, BAITINGER LA et al.: Salmeterol response is not affected by p2-adrenergic receptor genotype in subjects with persistent asthma. J. Allergy Clin. Immunol. (2006) 118:809-816.
38. BLEECKER ER, POSTMA DS, LAWRENCE RM, MEYERS DA, AMBROSE HJ, GOLDMAN M: Effect of ADRB2 polymorphisms on response to long-acting p2-agonist therapy. Lancet (2007) (In Press).
39. HANCOX RJ: Interactions between corticosteroids and p2-agonists. Clin. Rev. Allergy Immunol. (2006) 31:231-246.
40. WENZEL S: Severe asthma in adults. Am. J. Respir. Crit. Care Med. (2005) 172:149-160.
41. WENZEL S: Physiologic and pathologic abnormalities in severe asthma. Clin. Chest Med. (2006) 27:29-40.
42. GREEN RH, BRIGHTLING CE, WOLTMANN G et al.: Analysis of induced sputum in adults with asthma: identification of subgroup with isolated sputum neutrophilia and poor response to inhaled corticosteroids. Thorax (2002) 57:875-879.
43. DRAZEN JM, SILVERMAN EK, LEE TH: Heterogeneity of therapeutic responses in asthma. Br. Med. Bull. (2000) 56:1054-1070.
44. WEISS ST, LITONJUA AA, LANGE C et al.: Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J. (2006) 6:311-326.
45. LIMA JJ, THOMASON DB, MOHAMED MH et al.: Impact of genetic polymorphisms of the β2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin. Pharmacol. Ther. (1999) 65:519-525.
46. MARTINEZ FD, GRAVES PE, BALDINI M, SOLOMON S, ERICKSON R: Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J. Clin. Invest. (1997) 100:3184-3188.
47. TAYLOR DR, EPTON MJ, KENNEDY MA et al.: Bronchodilator response in relation to β2-adrenoceptor haplotype in patients with asthma. Am. J. Respir. Crit. Care Med. (2005) 172(6):700-703.
48. EISENSTADT WS: Some observations on a new syndrome-respiratory medicamentosa. Ann. Allergy (1969) 27:188-190.
49. REISMAN RE: Asthma induced by adrenergic aerosols. J. Allergy (1970) 46:162-177.
50. TATTERSFIELD AE, LOFDAHL CG, POSTMA DS et al.: Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial. Lancet (2001) 357:257-261.